J, N., YW, K., J, G., MLH, H., A, J., S, V., . . . DN, O. (2025). Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: The PARTNER study. BMJ open, 15(5), e098457. https://doi.org/10.1136/bmjopen-2024-098457
Chicago Style (17th ed.) CitationJ, Ngan, et al. "Rationale and Design of a Randomised Phase II Multicentre Crossover Trial Investigating a Sodium-glucose Co-transporter 2 Inhibitor, Dapagliflozin, Combined with a Novel Continuous Ketone Monitor in Adults with Type 1 Diabetes to Reduce the Risk of Diabetic Ketoacidosis: The PARTNER Study." BMJ Open 15, no. 5 (2025): e098457. https://doi.org/10.1136/bmjopen-2024-098457.
MLA (9th ed.) CitationJ, Ngan, et al. "Rationale and Design of a Randomised Phase II Multicentre Crossover Trial Investigating a Sodium-glucose Co-transporter 2 Inhibitor, Dapagliflozin, Combined with a Novel Continuous Ketone Monitor in Adults with Type 1 Diabetes to Reduce the Risk of Diabetic Ketoacidosis: The PARTNER Study." BMJ Open, vol. 15, no. 5, 2025, p. e098457, https://doi.org/10.1136/bmjopen-2024-098457.
